Triple threat against stomach cancer: chemo, Low-Dose radiation, and immunotherapy
NCT ID NCT07408609
First seen Feb 15, 2026 · Last updated May 15, 2026 · Updated 13 times
Summary
This study tests whether adding low-dose radiation and an immunotherapy drug (tislelizumab) to standard chemotherapy improves outcomes for people with locally advanced stomach or gastroesophageal junction cancer. About 114 participants will be randomly assigned to receive either the combination therapy or chemotherapy alone before and after surgery. The main goal is to see if the combination leads to a higher rate of complete tumor disappearance at the time of surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.